Effectiveness and safety of the treatment of chronic hepatitis C in patients infected with the human immunodeficiency virus comparing two types of pegylated interferon and ribavirin

Trial Profile

Effectiveness and safety of the treatment of chronic hepatitis C in patients infected with the human immunodeficiency virus comparing two types of pegylated interferon and ribavirin

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2009

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PEGIFN-VCH-VIH
  • Most Recent Events

    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top